Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a ...

D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from ...

EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the ...

Morgan Stanley analyst Judah Frommer lowered the firm’s price target on 4D Molecular (FDMT) to $6 from $8 and keeps an Underweight rating on the shares after the company announced a pipeline ...

Weiss Ratings restated their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report ...

4D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular edema (DME) candidate 4D-150. The company will only have to conduct a ...

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on 4D Molecular Therapeutics (NASDAQ:FDMT) in the last three months. Summarizing their recent ...

Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its ...

On Wednesday, Goldman Sachs reinstated coverage on 4D Molecular Therapeutics (NASDAQ:FDMT), assigning a Buy rating and a price target of $81.00. This move marks a shift from their ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

4D Molecular Therapeutics (NASDAQ:FDMT) finds itself at a critical juncture as it advances its gene therapy pipeline targeting large markets in ophthalmology and rare diseases. According to ...